US FDA Expands In-Person Meeting Eligibility, But So Far No Takers

 
• By Derrick Gingery
virtual meeting
Pre-ANDA product development and ANDA pre-submission meetings join Type A and Biosimilar Product Development Type 1 meetings as eligible for the hybrid format. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics